{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-23-000038","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.624960+00:00","generated_at":"2026-06-08T13:58:31.748848+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xencor sells Ultomiris and Monjuvi royalty rights to OMERS for $215M upfront","bullets":["OMERS pays $192.5M for Ultomiris royalties from July 2023 through end-2025, then annual caps starting in 2026.","OMERS pays $22.5M for Monjuvi royalties until OMERS receives 1.3x purchase price; excess reverts to Xencor.","Xencor eligible for an additional $12M milestone from OMERS if certain Ultomiris sales targets met.","Xencor retains economic upside above annual royalty caps ($35M from 2026-2028, $12M from 2029 onward).","Cash proceeds strengthen balance sheet to fund internal pipeline programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-23-000038","json":"https://secwatch.observer/filing/0001326732-23-000038.json","markdown":"https://secwatch.observer/filing/0001326732-23-000038.md","text":"https://secwatch.observer/filing/0001326732-23-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673223000038/0001326732-23-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673223000038/xncr-20231103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T13:58:31.748848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7d5792b64b9fa5aa3a5046c0caacfaa38314025c","claim":"Xencor Inc entered into Ultomiris Agreement with OCM Life Sciences Portfolio LP valued at upfront payment of $192.5 million (effective 2023-11-03).","evidence_excerpt":"On November 3, 2023, Xencor, Inc. (the “Company”) and OCM Life Sciences Portfolio LP, an investment vehicle of OMERS, one of Canada’s largest defined benefit pension plans (“OMERS”) entered into a royalty purchase agreement (the “Ultomiris Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326732/000132673223000038/0001326732-23-000038-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"OCM Life Sciences Portfolio LP"},{"label":"Value","value":"upfront payment of $192.5 million"},{"label":"Effective","value":"2023-11-03"}],"fact_type":"material_agreement"},{"claim_id":"dd75acb854c146eb58966e885774ff33214283ae","claim":"Xencor Inc entered into Monjuvi Agreement with OCM Life Sciences Portfolio LP valued at upfront payment of $22.5 million (effective 2023-11-03).","evidence_excerpt":"(the “Company”) and OCM Life Sciences Portfolio LP, an investment vehicle of OMERS, one of Canada’s largest defined benefit pension plans (“OMERS”) entered into a royalty purchase agreement (the “Ultomiris Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326732/000132673223000038/0001326732-23-000038-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"OCM Life Sciences Portfolio LP"},{"label":"Value","value":"upfront payment of $22.5 million"},{"label":"Effective","value":"2023-11-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}